Apr 9 |
Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
|
Mar 17 |
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
|
Mar 14 |
Aadi Bioscience Full Year 2023 Earnings: US$2.44 loss per share (vs US$2.69 loss in FY 2022)
|
Mar 13 |
Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript
|
Mar 13 |
Aadi Bioscience GAAP EPS of -$0.60 beats by $0.05, revenue of $6.33M beats by $0.03M
|
Mar 13 |
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
|
Mar 13 |
Earnings Scheduled For March 13, 2024
|
Mar 12 |
Aadi Bioscience Q4 2023 Earnings Preview
|
Mar 6 |
Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update
|
Mar 5 |
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
|